How I treat FLT3-mutated AML

Keith Pratz, Mark J Levis

Research output: Contribution to journalArticle

Abstract

FLT3-mutated acute myeloid leukemia (AML), despite not being recognized as a distinct entity in the World Health Organization (WHO) classification system, is readily recognized as a particular challenge by clinical specialists who treat acute leukemia. This is especially true with regards to the patients harboring the most common type of FLT3 mutation, the internal tandem duplication (FLT3-ITD) mutation. Here we present 4 patient cases from our institution and discuss how our management reflects what we have learned about this subtype of the disease. We also reflect on how we anticipate the management might change in the near future, with the emergence of clinically useful tyrosine kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)565-571
Number of pages7
JournalBlood
Volume129
Issue number5
DOIs
StatePublished - Feb 2 2017

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'How I treat FLT3-mutated AML'. Together they form a unique fingerprint.

  • Cite this